The Journal of Medical Investigation
Online ISSN : 1349-6867
Print ISSN : 1343-1420
ISSN-L : 1343-1420
Effectiveness and safety of romosozumab followed by 2 years of sequential therapy with denosumab in a real-world setting to investigate the influence of prior treatments
Kazuaki Mineta, Toshihiko Nishisho, Masahiko Okada, Mitsuhiro Kamada, Koichi Sairyo
著者情報
ジャーナル フリー

2026 年 73 巻 3.4 号 p. 425-433

詳細
抄録

Objective:This prospective observational study investigated the effects of prior osteoporosis treatment on subsequent treatment with romosozumab (ROMO) followed by denosumab (DMAb) in female patients with primary osteoporosis. Methods:Treatment-naïve patients (Naïve group, n=15) and patients previously treated with teriparatide (TPTD group, n=15) or DMAb (DMAb group, n=41) were switched to ROMO for 12 months, followed by DMAb for 24 months. Bone mineral density (BMD) in the lumbar spine (LS) and total hip (TH) was evaluated every 6 months for 36 months. Results:At 12 months (after ROMO treatment) and 36 months (after ROMO+DMAb therapy), LS BMD respectively increased by 9.5% and 15.0% in the Naïve group, 9.7% and 18.6% in the TPTD group, and 4.3% and 8.3% in the DMAb group. The corresponding increases in TH BMD were 3.7% and 8.8%, 0.9% and 6.2%, and 0.9% and 4.6%. Conclusion:Previous therapy affected the BMD increase after treatment with ROMO but did not influence the increase after treatment with DMAb following ROMO. J. Med. Invest. 73 : 425-433, August, 2026

著者関連情報
© by The University of Tokushima Faculty of Medicine
前の記事 次の記事
feedback
Top